IL164256A0 - Combined dna/protein compositions - Google Patents

Combined dna/protein compositions

Info

Publication number: IL164256A0
Authority: IL; Israel
Prior art keywords: dna; combined dna; combined; protein compositions; protein
Prior art date: 2002-03-28

Application number

IL16425603A

Other languages

English (en)

Original Assignee

Brenntag Biosector As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2003-03-28

Publication date

2005-12-18

2003-03-28 Application filed by Brenntag Biosector As filed Critical Brenntag Biosector As

2005-12-18 Publication of IL164256A0 publication Critical patent/IL164256A0/xx

Links

239000000203 mixture Substances 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
102000004169 proteins and genes Human genes 0.000 title abstract 2
108010041986 DNA Vaccines Proteins 0.000 abstract 3
229940021995 DNA vaccine Drugs 0.000 abstract 3
239000002671 adjuvant Substances 0.000 abstract 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
229910052782 aluminium Inorganic materials 0.000 abstract 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000005847 immunogenicity Effects 0.000 abstract 1
229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
239000011707 mineral Substances 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
229940023143 protein vaccine Drugs 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

IL16425603A 2002-03-28 2003-03-28 Combined dna/protein compositions IL164256A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02076276		2002-03-28
EP03075383		2003-02-10
PCT/EP2003/003353 WO2003082327A2 (en)	2002-03-28	2003-03-28	Combined dna/protein vaccine compositions

Publications (1)

Publication Number	Publication Date
IL164256A0 true IL164256A0 (en)	2005-12-18

Family

ID=28676388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL16425603A IL164256A0 (en)	2002-03-28	2003-03-28	Combined dna/protein compositions

Country Status (9)

Country	Link
US (1)	US20050129712A1 (da)
EP (1)	EP1490100B1 (da)
AT (1)	ATE538808T1 (da)
AU (1)	AU2003224017A1 (da)
CA (1)	CA2480690A1 (da)
DK (1)	DK1490100T3 (da)
ES (1)	ES2379346T3 (da)
IL (1)	IL164256A0 (da)
WO (1)	WO2003082327A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9238679B2 (en)	2011-02-11	2016-01-19	The Trustees Of The University Of Pennslyvania	Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA032364B1 (ru)	2011-02-11	2019-05-31	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
CN111388662B (zh) *	2020-03-12	2023-03-10	潍坊华英生物科技有限公司	一种小鹅瘟病毒的复合疫苗及卵黄抗体制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG48365A1 (en) *	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
EP0880360B1 (en) *	1996-02-12	2002-10-09	Cobra Therapeutics Limited	Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
GB9726555D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Vaccine
WO2000002591A1 (en) *	1998-07-09	2000-01-20	Merck & Co., Inc.	Polynucleotide vaccine formulations
GB9910375D0 (en) *	1999-05-05	1999-06-30	Lindahl Gunnar	Vaccine composition

2003
- 2003-03-28 IL IL16425603A patent/IL164256A0/xx unknown
- 2003-03-28 WO PCT/EP2003/003353 patent/WO2003082327A2/en not_active Ceased
- 2003-03-28 DK DK03720397.3T patent/DK1490100T3/da active
- 2003-03-28 AU AU2003224017A patent/AU2003224017A1/en not_active Abandoned
- 2003-03-28 CA CA002480690A patent/CA2480690A1/en not_active Abandoned
- 2003-03-28 US US10/509,498 patent/US20050129712A1/en not_active Abandoned
- 2003-03-28 ES ES03720397T patent/ES2379346T3/es not_active Expired - Lifetime
- 2003-03-28 AT AT03720397T patent/ATE538808T1/de active
- 2003-03-28 EP EP03720397A patent/EP1490100B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1490100A2 (en)	2004-12-29
WO2003082327A2 (en)	2003-10-09
US20050129712A1 (en)	2005-06-16
ES2379346T3 (es)	2012-04-25
AU2003224017A1 (en)	2003-10-13
DK1490100T3 (da)	2012-03-12
EP1490100B1 (en)	2011-12-28
ATE538808T1 (de)	2012-01-15
WO2003082327A3 (en)	2004-03-04
CA2480690A1 (en)	2003-10-09

Publication	Publication Date	Title
US20230210965A1 (en)	2023-07-06	PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT
IL150602A (en)	2010-12-30	Proteosome influenza vaccine, method for preparing such and use thereof
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
BR0311995A (pt)	2005-04-05	Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
PT1361890E (pt)	2011-06-07	Formulações vacinais de influenza para distribuição intradérmica
WO2000020027A3 (en)	2000-10-12	Methods for therapeutic vaccination
RU2009144125A (ru)	2011-07-27	Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
WO2008057235A3 (en)	2008-08-07	Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2005007673A3 (en)	2007-11-22	Immunogenic peptides
GB2386072A (en)	2003-09-10	Novel vaccine
WO2006136460A3 (en)	2007-06-14	New adjuvant
WO2004085466A8 (en)	2005-10-13	Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
IL164256A0 (en)	2005-12-18	Combined dna/protein compositions
WO2003101482A3 (en)	2004-02-05	Liposome vaccine formulations for fin-fish
WO2004007726A3 (en)	2004-02-19	Brachyspira hyodysenteriae vaccine
Buaklin et al.	2014	Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein
IL149415A0 (en)	2002-11-10	Adjuvanted genetic vaccines
WO2003090778A3 (en)	2004-01-22	Dna vaccine combined with an inducer of tumor cell apoptosis
SI1227840T1 (sl)	2008-02-29	Genetske vakcine z adjuvansom
HK1141793A (en)	2010-11-19	Cationic lipids compositions and methods for enhancing immune responses to vaccines